Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Comparison of Post-Operative Pain Occurrence After Single Visit Root Canal Treatment

  • Read more about Comparison of Post-Operative Pain Occurrence After Single Visit Root Canal Treatment

Dysfunctional Breathing in Post COVID-19 Condition.

  • Read more about Dysfunctional Breathing in Post COVID-19 Condition.

Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)

  • Read more about Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)

Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)

  • Read more about Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)

Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy

  • Read more about Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  • Read more about A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant

  • Read more about Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant

Agenus, Inc.

By jpalfreyman on Fri, 01/10/2025 - 15:21
  • Read more about Agenus, Inc.

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

  • Read more about Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

IPGx PILOT Whole Genome Sequencing Extension Cohort

  • Read more about IPGx PILOT Whole Genome Sequencing Extension Cohort

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 28
  • Page 29
  • Page 30
  • Page 31
  • Current page 32
  • Page 33
  • Page 34
  • Page 35
  • Page 36
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA